Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
about
Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy.Angiotensin II inhibits insulin-stimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms.Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function.Spironolactone and colitis: increased mortality in rodents and in humans.Effect of exercise on kidney function, oxidative stress, and inflammation in type 2 diabetic KK-A(y) miceEmerging drugs for diabetic nephropathy.Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited.Diabetic nephropathy: What does the future hold?Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive ratsOxidative stress in diabetic nephropathy.Gene expression profiling following maternal deprivation: involvement of the brain Renin-Angiotensin system.Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets.The renal effects of blood glucose-lowering plant-derived extracts in diabetes mellitus--an overview.Current therapeutic interventions in the glycation pathway: evidence from clinical studies.Nox4 and diabetic nephropathy: with a friend like this, who needs enemies?Have we reached the limits for the treatment of diabetic nephropathy?The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?Effects of methanolic extracts from edible plants on endogenous secretory receptor for advanced glycation end products induced by the high glucose incubation in human endothelial cells.Effect of the Direct Renin Inhibitor Aliskiren on Urinary Albumin Excretion in Spontaneous Type 2 Diabetic KK-A (y) Mouse.Regulatory networks and complex interactions between the insulin and angiotensin II signalling systems: models and implications for hypertension and diabetes.NOX1 abet mesangial fibrogenesis via iNOS induction in diabetes.Candesartan stimulates reparative angiogenesis in ischemic retinopathy model: role of hemeoxygenase-1 (HO-1).Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats.Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade.Effects of candesartan cilexetil and amlodipine orotate on receptor for advanced glycation end products expression in the aortic wall of Otsuka Long-Evans Tokushima Fatty (OETFF) type 2 diabetic rats.Effects of methanolic extracts of edible plants on RAGE in high-glucose-induced human endothelial cells.AGE-RAGE Stress, Stressors, and Antistressors in Health and Disease.Role of the TNF pathway in the progression of diabetic nephropathy in KK-A(y) mice.Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)/Ta mice.Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy
P2860
Q33348438-C5498D80-E0B4-4CFB-82D0-B347BCDE47B9Q33552248-15AA1D35-E463-4922-B4CB-07E503A10F2DQ34355343-30854E43-71F3-4E40-AA6F-479E02D442FDQ35785467-FF278A76-6CF0-491B-85BB-B0B7E00F847CQ36140981-E01537CF-356D-48AA-B871-7468FEC47B1AQ36302838-3763C8D0-6AC3-4B23-B962-9FF882488603Q36431827-B7F4D1AA-DDCE-4FAB-9449-122D045483B9Q36441616-AFE5D927-F315-4C31-9833-1D0AF5CF8A07Q36746679-5AEBA188-FE81-4A9C-9A3A-1F5128984C04Q37003803-FC76D282-EEDF-46A5-A9F0-85DA4897D728Q37214203-15029109-58BC-41D2-8865-FA9372046116Q37225236-E4638C24-659B-479C-930B-DFC18693AD8BQ37611981-83BC8724-9990-41C2-861D-FB87F29B8A20Q37683784-300D215B-47FD-4F16-B2B2-49D3D6AAC938Q38070906-8E78626B-2263-4ADA-B32C-61BF9F90B9C1Q38092960-C829A201-00CA-45E1-AC3B-503BB2D6C390Q38189884-983ACDDB-8D86-4E75-99EB-63618DD8A35AQ38771740-B7CCFDD2-A800-4CAF-B4A7-675189C2B935Q39158946-8D51D51C-EB06-4C8A-8103-80C1154F24B6Q39684307-EDFA75D4-4ECC-4141-B1F4-CF90634A2D77Q41852636-728C1F96-A7A0-4731-B14F-4C1E6F233527Q41853350-964EEE47-A9D2-41AA-B14C-263F91D063C2Q42440485-4A843438-7284-424F-918F-FF8AD5259626Q42739089-EA91A591-1146-4E58-9CAE-F35C35CE1826Q45915450-52547296-D8FC-4AAF-86F9-17F6A54070A7Q45965532-C3B4F77B-9F42-4911-9B18-E13EC1C36E9CQ46582498-28CA23C4-EFA6-4F27-972C-B9BEBCA4F8BCQ46664088-2320AA19-5590-4288-B0E7-065C217D07BDQ51747235-FC5548FC-B2EA-49CA-940C-5CDA6C10A109Q53061535-97BDA6B7-82AB-4083-ACE9-59C788CCB2D4Q54642763-ECB6B966-3A07-4874-B8BC-098E70D8A22FQ59034810-573B4050-26FE-4AED-948F-F4B49B7D2F3B
P2860
Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Candesartan reduced advanced g ...... in type 2 diabetic KK/Ta mice.
@en
Candesartan reduced advanced g ...... in type 2 diabetic KK/Ta mice.
@nl
type
label
Candesartan reduced advanced g ...... in type 2 diabetic KK/Ta mice.
@en
Candesartan reduced advanced g ...... in type 2 diabetic KK/Ta mice.
@nl
prefLabel
Candesartan reduced advanced g ...... in type 2 diabetic KK/Ta mice.
@en
Candesartan reduced advanced g ...... in type 2 diabetic KK/Ta mice.
@nl
P2093
P2860
P356
P1476
Candesartan reduced advanced g ...... in type 2 diabetic KK/Ta mice.
@en
P2093
Li Ning Wang
Michifumi Yamashita
Michimasa Kobayashi
Qiuling Fan
Satoshi Horikoshi
Tomohito Gohda
Yasuhiko Tomino
Yusuke Suzuki
P2860
P304
P356
10.1093/NDT/GFH499
P407
P577
2004-12-01T00:00:00Z